What is a stock summary page? Click here for an overview.
Business Description
scPharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US8106481059
Compare
Compare
Traded in other countries / regions
SCPH.USA2SX.Germany Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2017-11-17Description
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.44 | |||||
| Equity-to-Asset | 0.12 | |||||
| Debt-to-Equity | 3.96 | |||||
| Debt-to-EBITDA | -0.68 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -5 | |||||
| Beneish M-Score | 0.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -23.9 | |||||
| 3-Year EPS without NRI Growth Rate | -16.6 | |||||
| 3-Year FCF Growth Rate | -16.9 | |||||
| 3-Year Book Growth Rate | -49.5 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 76.71 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.38 | |||||
| 9-Day RSI | 47.56 | |||||
| 14-Day RSI | 45.37 | |||||
| 3-1 Month Momentum % | -8.81 | |||||
| 6-1 Month Momentum % | -28.57 | |||||
| 12-1 Month Momentum % | -31.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.12 | |||||
| Quick Ratio | 6.18 | |||||
| Cash Ratio | 5.09 | |||||
| Days Inventory | 422.35 | |||||
| Days Sales Outstanding | 74.98 | |||||
| Days Payable | 134.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22.3 | |||||
| Shareholder Yield % | -49.23 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.73 | |||||
| Operating Margin % | -178.29 | |||||
| Net Margin % | -234.36 | |||||
| FCF Margin % | -194.15 | |||||
| ROE % | -370.01 | |||||
| ROA % | -90.39 | |||||
| ROIC % | -388.81 | |||||
| 3-Year ROIIC % | -379.62 | |||||
| ROC (Joel Greenblatt) % | -640.09 | |||||
| ROCE % | -96.38 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.08 | |||||
| PB Ratio | 9.3 | |||||
| Price-to-Tangible-Book | 9.3 | |||||
| EV-to-EBIT | -1.32 | |||||
| EV-to-Forward-EBIT | -7.14 | |||||
| EV-to-EBITDA | -1.33 | |||||
| EV-to-Revenue | 2.83 | |||||
| EV-to-Forward-Revenue | 1.43 | |||||
| EV-to-FCF | -1.46 | |||||
| Price-to-Net-Current-Asset-Value | 10.91 | |||||
| Earnings Yield (Greenblatt) % | -75.76 | |||||
| FCF Yield % | -55.89 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SCPH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
scPharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 36.332 | ||
| EPS (TTM) ($) | -1.9 | ||
| Beta | 0.23 | ||
| 3-Year Sharpe Ratio | -0.33 | ||
| 3-Year Sortino Ratio | -0.48 | ||
| Volatility % | 35.7 | ||
| 14-Day RSI | 45.37 | ||
| 14-Day ATR ($) | 0.211154 | ||
| 20-Day SMA ($) | 2.44925 | ||
| 12-1 Month Momentum % | -31.03 | ||
| 52-Week Range ($) | 1.94 - 5.65 | ||
| Shares Outstanding (Mil) | 50.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
scPharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
scPharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
scPharmaceuticals Inc Frequently Asked Questions
What is scPharmaceuticals Inc(SCPH)'s stock price today?
The current price of SCPH is $2.51. The 52 week high of SCPH is $5.65 and 52 week low is $1.94.
When is next earnings date of scPharmaceuticals Inc(SCPH)?
The next earnings date of scPharmaceuticals Inc(SCPH) is 2025-05-14 Est..
Does scPharmaceuticals Inc(SCPH) pay dividends? If so, how much?
scPharmaceuticals Inc(SCPH) does not pay dividend.
Guru Commentaries on NAS:SCPH
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers